Frontage Laboratories Opens New CRDMO Facility in Exton, PA Enhancing Biotech Capabilities
On May 22, 2025, Frontage Laboratories, Inc. celebrated the grand opening of its new state-of-the-art Contract Research, Development and Manufacturing Organization (CRDMO) facility located in Exton, Pennsylvania. This ambitious expansion, featuring a 46,300-square-foot complex, underscores Frontage's commitment to driving advancements in the pharmaceutical and biotechnology sectors.
The new facility at 240 Sierra Drive comprises nine Good Manufacturing Practice (GMP) suites, including two specialized for high-potent compounds, two aseptic suites, and five non-sterile suites. This design allows the facility to support a diverse range of manufacturing requirements, from injectables and tablets to creams, gels, and ophthalmic preparations. Additionally, it houses two formulation development laboratories and three analytical labs, including a dedicated micro lab.
This comprehensive approach ensures that Frontage can provide a one-stop solution for pharmaceutical and biotech clients, covering all essential aspects of clinical supply, such as formulation development, manufacturing, analytical testing, packaging, labeling, distribution, and storage. As the demand for efficient drug development continues to grow, Frontage's expanded capabilities are set to enhance overall service delivery to its clients.
Dr. Song Li, the Founder and Executive Chairman of Frontage, expressed gratitude to those who attended the event and emphasized the significance of the new facility in the context of clinical trial material supply. "This marks a major milestone for us in the CDMO sector," stated Dr. Li. The sentiments were echoed by Dr. Wentao Zhang, Co-CEO of Frontage Laboratories, who highlighted the strategic intent behind this expansion. "By opening this advanced facility, we significantly enhance our manufacturing capacities and are better positioned to respond swiftly to our clients’ evolving requirements."
Continuing its legacy of innovation, Frontage now offers more than just traditional manufacturing services. The organization complements its new CRDMO capabilities with existing offerings, including drug substance synthesis and safety toxicology studies, ensuring clients receive comprehensive support throughout the drug development lifecycle.
With a rich history of over 25 years in the industry, Frontage Laboratories, Inc. serves as a global leader in integrated product development services. This includes a robust portfolio that spans drug discovery, analytical services, clinical trials, and bioanalytical support, ensuring a seamless journey from initial exploration to regulatory approval across various territories, including the US, Canada, Europe, and Asia.
As Frontage continues to expand its global presence, now boasting 26 facilities worldwide, it emphasizes its role in not just meeting but anticipating the challenges faced by pharmaceutical and biotech companies. This proactive strategy positions them as crucial partners in the race toward innovation and therapeutic delivery.
For further details or inquiries, please visit Frontage’s official website at www.frontagelab.com, or contact their media relations team.
In conclusion, the opening of this state-of-the-art CRDMO facility marks an important chapter for Frontage Laboratories, further solidifying its role as a pivotal player in the dynamic landscape of pharmaceutical and biotechnological advancement.
The new facility at 240 Sierra Drive comprises nine Good Manufacturing Practice (GMP) suites, including two specialized for high-potent compounds, two aseptic suites, and five non-sterile suites. This design allows the facility to support a diverse range of manufacturing requirements, from injectables and tablets to creams, gels, and ophthalmic preparations. Additionally, it houses two formulation development laboratories and three analytical labs, including a dedicated micro lab.
This comprehensive approach ensures that Frontage can provide a one-stop solution for pharmaceutical and biotech clients, covering all essential aspects of clinical supply, such as formulation development, manufacturing, analytical testing, packaging, labeling, distribution, and storage. As the demand for efficient drug development continues to grow, Frontage's expanded capabilities are set to enhance overall service delivery to its clients.
Dr. Song Li, the Founder and Executive Chairman of Frontage, expressed gratitude to those who attended the event and emphasized the significance of the new facility in the context of clinical trial material supply. "This marks a major milestone for us in the CDMO sector," stated Dr. Li. The sentiments were echoed by Dr. Wentao Zhang, Co-CEO of Frontage Laboratories, who highlighted the strategic intent behind this expansion. "By opening this advanced facility, we significantly enhance our manufacturing capacities and are better positioned to respond swiftly to our clients’ evolving requirements."
Continuing its legacy of innovation, Frontage now offers more than just traditional manufacturing services. The organization complements its new CRDMO capabilities with existing offerings, including drug substance synthesis and safety toxicology studies, ensuring clients receive comprehensive support throughout the drug development lifecycle.
With a rich history of over 25 years in the industry, Frontage Laboratories, Inc. serves as a global leader in integrated product development services. This includes a robust portfolio that spans drug discovery, analytical services, clinical trials, and bioanalytical support, ensuring a seamless journey from initial exploration to regulatory approval across various territories, including the US, Canada, Europe, and Asia.
As Frontage continues to expand its global presence, now boasting 26 facilities worldwide, it emphasizes its role in not just meeting but anticipating the challenges faced by pharmaceutical and biotech companies. This proactive strategy positions them as crucial partners in the race toward innovation and therapeutic delivery.
For further details or inquiries, please visit Frontage’s official website at www.frontagelab.com, or contact their media relations team.
In conclusion, the opening of this state-of-the-art CRDMO facility marks an important chapter for Frontage Laboratories, further solidifying its role as a pivotal player in the dynamic landscape of pharmaceutical and biotechnological advancement.
Topics General Business）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.